138 related articles for article (PubMed ID: 18663536)
1. A PDE model for imatinib-treated chronic myelogenous leukemia.
Kim PS; Lee PP; Levy D
Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
[TBL] [Abstract][Full Text] [Related]
2. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models.
Kim PS; Lee PP; Levy D
Bull Math Biol; 2008 Apr; 70(3):728-44. PubMed ID: 18060460
[TBL] [Abstract][Full Text] [Related]
3. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
4. Stability analysis of a simplified yet complete model for chronic myelogenous leukemia.
Doumic-Jauffret M; Kim PS; Perthame B
Bull Math Biol; 2010 Oct; 72(7):1732-59. PubMed ID: 20077027
[TBL] [Abstract][Full Text] [Related]
5. Mathematical models of cancer stem cells.
Michor F
J Clin Oncol; 2008 Jun; 26(17):2854-61. PubMed ID: 18539964
[TBL] [Abstract][Full Text] [Related]
6. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
Holtz M; Forman SJ; Bhatia R
Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
[TBL] [Abstract][Full Text] [Related]
7. Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Moosavi MA; Yazdanparast R
Med Hypotheses; 2006; 67(6):1470-1. PubMed ID: 16919395
[No Abstract] [Full Text] [Related]
8. Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells.
Kobayashi S; Sato K; Kobayashi A; Osawa Y; Nakamura Y; Kimura F
Ann Hematol; 2011 Mar; 90(3):367-8. PubMed ID: 20556391
[No Abstract] [Full Text] [Related]
9. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
10. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
11. Optimal control for resistance and suboptimal response in CML.
Aïnseba B; Benosman C
Math Biosci; 2010 Oct; 227(2):81-93. PubMed ID: 20638391
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia blast crisis arises from progenitors.
Michor F
Stem Cells; 2007 May; 25(5):1114-8. PubMed ID: 17218393
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
14. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.
Bertz J; Zang C; Liu H; Wächter M; Possinger K; Koeffler HP; Elstner E
Leuk Res; 2009 May; 33(5):686-92. PubMed ID: 19131110
[TBL] [Abstract][Full Text] [Related]
15. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
16. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
17. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
Nanda S; Moore H; Lenhart S
Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
[TBL] [Abstract][Full Text] [Related]
18. Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.
Elliot V; Marin D; Horncastle D; Elderfield K; Howard J; Apperley JF; Lampert IA; Naresh KN
Histopathology; 2007 May; 50(6):810-2. PubMed ID: 17376172
[No Abstract] [Full Text] [Related]
19. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
Buyukbayrak EE; Ergen B; Karsidag YK; Kars B; Turan C; Argon D
Arch Gynecol Obstet; 2008 Aug; 278(2):161-3. PubMed ID: 18193246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
